CHMP also issues two label extensions for darunavir
BEERSE, Belgium I September 29, 2014 I Janssen-Cilag International NV (Janssen) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a Positive Opinion recommending REZOLSTA™ (darunavir/cobicistat) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years or older. The CHMP also announced two label extensions for darunavir, a protease inhibitor marketed as PREZISTA® by Janssen.
REZOLSTA™ is a new once-daily, fixed-dose combination tablet containing darunavir and the pharmacokinetic enhancing or “boosting” agent cobicistat (marketed as Tybost™ by Gilead Sciences, Inc.). The Janssen filing was based on bioequivalence data evaluating the use of a darunavir and cobicistat fixed-dose combination tablet versus single agents, and a clinical study evaluating the safety and efficacy of cobicistat-boosted darunavir for the treatment of HIV-1 in adults with no darunavir resistance-associated mutations.
“People with HIV are living longer than ever before thanks to the development and introduction of effective HIV treatments,” said Christiane Moecklinghoff, M.D Ph.D, Medical Director, Virology, Janssen EMEA. “For this reason, expanding existing treatment options, especially those which will improve patients’ lives by simplifying regimens and supporting adherence are critical. If approved, this new treatment option eliminates the need to take a boosting agent in a separate tablet with once-daily darunavir, reducing the pill burden for patients. We look forward to a final decision from the European Commission in the coming months.”
The darunavir and cobicistat fixed-dose combination was approved in Canada in June 2014 under the name PREZCOBIX™, and is currently undergoing regulatory review by the FDA in the USA.
Janssen will continue to make darunavir available, as a single agent in tablets, so patients and their physicians can decide which HIV treatment regimen is best for them.
The CHMP has also issued two additional label extensions relating to darunavir. The first label extension is for the prescribing of once-daily dosing of darunavir/ritonavir in children aged 3-
About HIV
Since the beginning of the HIV epidemic, almost 75 million people have been infected with the HIV virus.[1] It is estimated that 35 million people are currently living with HIV globally, with 2.5 million people becoming newly infected each year.[1],[2]
About PREZISTA®(darunavir)
Darunavir is a protease inhibitor used for the treatment of human immunodeficiency virus (HIV-1) infection and can be taken with either ritonavir (indicated for use in adults and pediatric patients from the age of 3) or cobicistat (indicated for use in adults only). Darunavir received initial approval in Europe in 2007 for use in HIV-1 infected highly pre-treated patients, with later approvals for treatment-naïve and less experienced adult patients, and then for use in pediatric patients. Darunavir/ritonavir is approved for use in pediatric patients aged 3-17.
About Tybost[TM](cobicistat)
Tybost (cobicistat 150 mg tablets) is a cytochrome P450 3A (CYP3A) inhibitor. It boosts blood levels of atazanavir or darunavir by suppressing CYP3A, an enzyme that metabolizes these drugs in the body. Cobicistat acts only as a pharmacokinetic enhancer and has no antiviral activity. Cobicistat was developed by Gilead and is a pharmacokinetic enhancer or boosting agent used with the protease inhibitors darunavir and atazanavir for the treatment of HIV, and is also found in STRIBILD® (elvitegravir / cobicistat / emtricitabine / tenofovir). Gilead is responsible for the manufacture, development and commercialization of cobicistat as a stand-alone product.
About Janssen
At Janssen, we are dedicated to addressing some of the most important unmet medical needs in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world. Janssen-Cilag International NV is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
SOURCE: Janssen
Post Views: 196
CHMP also issues two label extensions for darunavir
BEERSE, Belgium I September 29, 2014 I Janssen-Cilag International NV (Janssen) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a Positive Opinion recommending REZOLSTA™ (darunavir/cobicistat) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years or older. The CHMP also announced two label extensions for darunavir, a protease inhibitor marketed as PREZISTA® by Janssen.
REZOLSTA™ is a new once-daily, fixed-dose combination tablet containing darunavir and the pharmacokinetic enhancing or “boosting” agent cobicistat (marketed as Tybost™ by Gilead Sciences, Inc.). The Janssen filing was based on bioequivalence data evaluating the use of a darunavir and cobicistat fixed-dose combination tablet versus single agents, and a clinical study evaluating the safety and efficacy of cobicistat-boosted darunavir for the treatment of HIV-1 in adults with no darunavir resistance-associated mutations.
“People with HIV are living longer than ever before thanks to the development and introduction of effective HIV treatments,” said Christiane Moecklinghoff, M.D Ph.D, Medical Director, Virology, Janssen EMEA. “For this reason, expanding existing treatment options, especially those which will improve patients’ lives by simplifying regimens and supporting adherence are critical. If approved, this new treatment option eliminates the need to take a boosting agent in a separate tablet with once-daily darunavir, reducing the pill burden for patients. We look forward to a final decision from the European Commission in the coming months.”
The darunavir and cobicistat fixed-dose combination was approved in Canada in June 2014 under the name PREZCOBIX™, and is currently undergoing regulatory review by the FDA in the USA.
Janssen will continue to make darunavir available, as a single agent in tablets, so patients and their physicians can decide which HIV treatment regimen is best for them.
The CHMP has also issued two additional label extensions relating to darunavir. The first label extension is for the prescribing of once-daily dosing of darunavir/ritonavir in children aged 3-
About HIV
Since the beginning of the HIV epidemic, almost 75 million people have been infected with the HIV virus.[1] It is estimated that 35 million people are currently living with HIV globally, with 2.5 million people becoming newly infected each year.[1],[2]
About PREZISTA®(darunavir)
Darunavir is a protease inhibitor used for the treatment of human immunodeficiency virus (HIV-1) infection and can be taken with either ritonavir (indicated for use in adults and pediatric patients from the age of 3) or cobicistat (indicated for use in adults only). Darunavir received initial approval in Europe in 2007 for use in HIV-1 infected highly pre-treated patients, with later approvals for treatment-naïve and less experienced adult patients, and then for use in pediatric patients. Darunavir/ritonavir is approved for use in pediatric patients aged 3-17.
About Tybost[TM](cobicistat)
Tybost (cobicistat 150 mg tablets) is a cytochrome P450 3A (CYP3A) inhibitor. It boosts blood levels of atazanavir or darunavir by suppressing CYP3A, an enzyme that metabolizes these drugs in the body. Cobicistat acts only as a pharmacokinetic enhancer and has no antiviral activity. Cobicistat was developed by Gilead and is a pharmacokinetic enhancer or boosting agent used with the protease inhibitors darunavir and atazanavir for the treatment of HIV, and is also found in STRIBILD® (elvitegravir / cobicistat / emtricitabine / tenofovir). Gilead is responsible for the manufacture, development and commercialization of cobicistat as a stand-alone product.
About Janssen
At Janssen, we are dedicated to addressing some of the most important unmet medical needs in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world. Janssen-Cilag International NV is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
SOURCE: Janssen
Post Views: 196
